AUG 17 2026
Deciphera Pharmaceuticals — tirabrutinib
for relapsed or refractory primary central nervous system lymphoma
About
Primary central nervous system lymphoma is an aggressive brain tumor that often occurs in people with weakened immune systems. Tirabrutinib is a drug designed to block a specific protein that helps these lymphoma cells grow and survive. By inhibiting this target, tirabrutinib could potentially slow the progression of this difficult-to-treat cancer.
Pivotal trial
The purpose of this clinical trial is to evaluate efficacy and safety of tirabrutinib alone compared with rituximab and temozolomide (R-TMZ) combination therapy in participants with Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL).
Source: ClinicalTrials.gov
Also in development
Drug Watch — recent news on tirabrutinib
- Tirabrutinib May Shift the R/R PCNSL Treatment Paradigm Toward Improved Tolerability - OncLive
- Tirabrutinib and CAR T-Cell Therapy Represent Potential Paradigm Shifts in R/R PCNSL - OncLive
- FDA Accepts New Drug Application for BTK Inhibitor Tirabrutinib - Targeted Oncology
- Tirabrutinib NDA Cleared by the FDA in Relapsed/Refractory PCNSL - CancerNetwork
- FDA accepts Deciphera’s NDA for tirabrutinib in rare aggressive brain lymphoma - indianpharmapost.com